Skip to main content
Poltreg S.A. logo

Poltreg S.A. — Investor Relations & Filings

Ticker · PTG ISIN · PLPLTRG00038 LEI · 259400XSAJTERJ42VZ86 WAR Professional, scientific and technical activities
Open in API
Filings indexed 361 across all filing types
Latest filing 2022-05-26 AGM Information
Country PL Poland
Listing WAR PTG

About Poltreg S.A.

https://poltreg.com/

Poltreg S.A. is a clinical-stage biotechnology company developing cellular therapies for a range of autoimmune diseases. The company specializes in treatments based on T-regulatory cells (Tregs), with an advanced pipeline of both polyclonal and engineered cell therapies. Its lead product, PTG-007, is an autologous Treg treatment being investigated for Type 1 Diabetes and Multiple Sclerosis. Poltreg is also advancing next-generation engineered therapies, including Chimeric Antigen Receptor T-regulatory cells (CAR-Tregs), for neuroinflammatory conditions such as Multiple Sclerosis and Amyotrophic Lateral Sclerosis (ALS). The company operates its own state-of-the-art, cGMP-certified manufacturing facility to produce its advanced therapy medicinal products.

Recent filings

Filing Released Lang Actions
Projekty uchwał ZWZA PolTREG S.A.
AGM Information Classification · 99% confidence The document text explicitly details 'PROJEKTY UCHWAŁ na Zwyczajne Walne Zgromadzenie' (Draft Resolutions for the Annual General Meeting) dated June 24, 2022. It contains multiple numbered resolutions ('UCHWAŁA Nr 1', 'UCHWAŁA Nr 2', etc.) covering procedural matters, approval of the 2021 annual reports, coverage of loss, and crucially, granting 'absolutorium' (discharge/approval of performance) to members of the Management Board and Supervisory Board for the 2021 fiscal year. The granting of absolutorium is a key function of an AGM. Since the document contains the draft resolutions intended for the meeting itself, the most appropriate classification is AGM Information (AGM-R). It is not a general regulatory filing (RNS) because it is highly specific to the AGM agenda and resolutions.
2022-05-26 Polish
Ogłoszenie o zwołaniu ZWZA PolTREG S.A.
AGM Information Classification · 100% confidence The document is titled "OGŁOSZENIE O ZWOŁANIU ZWYCZAJNEGO WALNEGO ZGROMADZENIA" (Announcement on Convening the Annual General Meeting) and details the date (June 24, 2022), time, location, and the detailed agenda (Porządek obrad) for the meeting. It also outlines procedures for shareholder participation, voting rights, and proxy instructions. This content directly corresponds to the definition of materials shared during an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2022-05-26 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia PolTREG S.A. na dzień 24 czerwca 2022 r. - Content (PL)
AGM Information Classification · 95% confidence The document text is in Polish and announces the convening of an 'Zwyczajne Walne Zgromadzenie Spółki' (Ordinary General Meeting of the Company) on June 24, 2022. It explicitly mentions the legal basis (Kodeks spółek handlowych) and states that the content of the announcement, draft resolutions, and documents for the meeting are attached to the current report ('niniejszym zwołuje... Emitent przekazuje w załączeniu do niniejszego raportu bieżącego'). Since this is a short announcement (650 chars) about convening a meeting and attaching the relevant materials (like proxy materials or agenda), it fits the description of an announcement related to a general meeting, which aligns best with 'AGM Information' (AGM-R) or potentially 'Proxy Solicitation & Information Statement' (PSI). Given the focus is on calling the meeting and attaching the associated documents, AGM-R is the most direct fit for an AGM announcement, although PSI covers the materials themselves. Since the text is calling the meeting, AGM-R is the primary classification for the event announcement itself.
2022-05-26 Polish
Rekomendacja projektu badawczego do ostatniego etapu ewaluacji w programie Horizon Europe - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a short announcement (1132 characters) from the Management Board of PolTREG S.A. informing the public that they received a recommendation from the European Health and Digital Executive Agency (HaDEA) for a research project under the Horizon Europe Program to proceed to the final evaluation stage. This is a specific update regarding a project and potential funding, but it is not a standard financial report (like 10-K, IR, ER) or a standard corporate action (like DIV, SHA, DIRS). It relates to the company's operations and potential future financing/research activities. Given the options, it is a general regulatory or operational announcement that doesn't fit the highly specific financial categories (like M&A, Capital Change, Earnings). Therefore, the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal notification of a significant operational/grant development.
2022-05-24 Polish
Otrzymanie od Europejskiej Agencji Leków pozytywnej porady naukowej w procedurze badawczej preparatu limfocytów T-regulatorowych (Scientific Advice CMC) - Content (PL)
Regulatory Filings Classification · 90% confidence The document is a short announcement (940 characters) from the Management Board of PolTREG S.A. informing that they received positive 'Scientific Advice CMC' from the European Medicines Agency (EMA) regarding the manufacturing process of their T-reg cell preparation (TregVag) for Type 1 Diabetes. This communication discusses regulatory feedback, scientific advice, and implications for future marketing authorization. It is not a full financial report (10-K, IR), an earnings release (ER), or a standard director's dealing (DIRS). Since it concerns specific regulatory feedback and scientific guidance related to product development and potential market authorization, it fits best under the general category for regulatory or scientific updates that aren't standard financial filings. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for specific, non-standard regulatory correspondence, although 'LTR' (Legal Proceedings Report) is sometimes used for regulatory interactions, this is clearly scientific/CMC advice, making RNS the best fit among the provided codes for a general regulatory update.
2022-05-22 Polish
Decyzja Urzędu Patentowego o udzieleniu patentu na wynalazek - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a formal announcement by the Management Board (Zarząd) of PolTREG S.A. regarding a decision by the Patent Office of the Republic of Poland (Urząd Patentowy Rzeczypospolitej Polskiej) granting a patent to the Medical University of Gdańsk (GUM) concerning a medical invention. The text details the patent grant, associated fees, and its relevance to the company's exclusive license agreement. This type of announcement, concerning legal rights, intellectual property, and potential future commercialization rights, fits best under the category of Legal Proceedings Report (LTR) or potentially Regulatory Filings (RNS) if LTR is too narrow. Since it specifically reports on the outcome of a legal/regulatory process (patent grant) that significantly impacts the company's core business (as mentioned in the IPO prospectus), LTR is the most precise fit, as it covers updates on significant legal matters. It is not an ER (no financial results), 10-K/IR (not a full report), CT (not a transcript), or DIV (not a dividend notice). It is a specific legal/IP update.
2022-05-16 Polish

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.